Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...

Further to our letter dated 20th February, 2025, wherein the Board recommend a final dividend of Rs. 55 per equity share, subject to the approval by the Members at the ensuing AGM, in this regard we ...

Sanofi Consumer Healthcare India Limited has informed the Exchange that the Record date for the purpose of Dividend is 28th April 2025 ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

FCB India, part of the IPG Group, has been awarded the creative mandate for Dulcoflex, a renowned brand in digestive health.

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.

The company announced its Q4 results after-market hours. Its shares ended 0.4% higher on Thursday at ₹4,759.35 on the BSE.

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.